Abstract
Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing. It is currently in phase III development for the first-line treatment of metastatic colorectal cancer. This article summarizes the clinical development program, which includes 2 global phase III studies, HORIZON II and HORIZON III, in the first-line treatment setting and a phase II study in second-line treatment (HORIZON I).
Trial registration:
ClinicalTrials.gov NCT00384176.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Female
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / therapeutic use
-
Male
-
Organoplatinum Compounds / therapeutic use
-
Quinazolines / therapeutic use*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Organoplatinum Compounds
-
Quinazolines
-
Bevacizumab
-
cediranib
-
Leucovorin
-
Fluorouracil
Associated data
-
ClinicalTrials.gov/NCT00384176